Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Malignant Disease × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 560 Carcinoma, Non-Small-Cell Lung 480 Ovarian Neoplasms 324 Lung Neoplasms 203 Neoplasms 150 Fallopian Tube Neoplasms 150 Triple Negative Breast Neoplasms 125 Esophageal Neoplasms 125 Stomach Neoplasms 120 Neoplasm Metastasis 118 Carcinoma, Ovarian Epithelial 113 Endometrial Neoplasms 94 Squamous Cell Carcinoma of Head and Neck 93 Uterine Cervical Neoplasms 79 Head and Neck Neoplasms 77 Esophageal Squamous Cell Carcinoma 74 Recurrence 48 Adenocarcinoma of Lung 47 Parkinson Disease 4, Autosomal Dominant Lewy Body 45 Melanoma 42 Carcinoma 42 Urinary Bladder Neoplasms 41 Adenocarcinoma Of Esophagus 35 Small Cell Lung Carcinoma 34 Carcinoma, Squamous Cell 34 Prostatic Neoplasms 32 Pancreatic Neoplasms 30 Breast Neoplasms, Male 28 Unspecified Adult Solid Tumor, Protocol Specific 27 Colorectal Neoplasms 25

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡